We are live on ! Find out more
6CM

683 Capital Management Portfolio holdings

AUM $1.92B
1-Year Est. Return 85.52%
This Fund
S&P 500
This Quarter Est. Return
+21.28%
1 Year Est. Return
+85.52%
3 Year Est. Return
+282.16%
5 Year Est. Return
+254.87%
10 Year Est. Return
+3,288.81%
AUM
$2.3B
AUM Growth
+$384M
Cap. Flow
+$216M
Cap. Flow %
9.39%
Top 10 Hldgs %
49.4%
Holding
255
New
116
Increased
33
Reduced
43
Closed
21

Top Buys

Rank Stock Value
1
KSPI icon
Kaspi.kz JSC
KSPI
+$20M
2
MREO
Mereo BioPharma
MREO
+$19.3M
3
BDX icon
Becton Dickinson
BDX
+$17.1M
4
SUNC
SunocoCorp LLC
SUNC
+$11.8M
5
MOH icon
Molina Healthcare
MOH
+$8.88M

Top Sells

Rank Stock Value
1
WDC icon
Western Digital
WDC
+$29.7M
2
QURE icon
uniQure
QURE
+$26.4M
3
LLY icon
Eli Lilly
LLY
+$21.8M
4
BBIO icon
BridgeBio Pharma
BBIO
+$19.6M
5
SNDK
Sandisk
SNDK
+$16.4M

Sector Composition

Rank Sector Weight
1 Healthcare 21.71%
2 Financials 6.94%
3 Consumer Discretionary 6.7%
4 Industrials 3.7%
5 Technology 3.18%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PPIH
126
Perma-Pipe International
PPIH
$210M
$1.12M 0.05%
+36,954
New +$1.01M
FBRX icon
127
Forte Biosciences
FBRX
$1.57B
$1.09M 0.05%
+40,000
New +$701K
KYTX icon
128
Kyverna Therapeutics
KYTX
$464M
$1.08M 0.05%
+114,900
New +$853K
UMAC icon
129
Unusual Machines
UMAC
$1.23B
$1.08M 0.05%
+84,751
New +$994K
ACHV icon
130
Achieve Life Sciences
ACHV
$684M
$1.07M 0.05%
+214,897
New +$937K
DIBS icon
131
1stdibs.com
DIBS
$174M
$1.05M 0.05%
+175,786
New +$791K
CTNM
132
Contineum Therapeutics
CTNM
$574M
$1.05M 0.05%
+91,442
New +$1.04M
LODE icon
133
Comstock
LODE
$236M
$1.04M 0.05%
+276,243
New +$939K
AVTX icon
134
Avalo Therapeutics
AVTX
$997M
$1.03M 0.04%
+56,850
New +$960K
PYXS icon
135
Pyxis Oncology
PYXS
$198M
$1.03M 0.04%
891,910
+366,910
+70% +$1.29M
MRAM icon
136
Everspin Technologies
MRAM
$378M
$1.02M 0.04%
+109,943
New +$1.05M
LWAC
137
LightWave Acquisition Corp
LWAC
$309M
$1M 0.04%
100,000
– –
IMRX icon
138
Immuneering
IMRX
$284M
$992K 0.04%
+150,697
New +$968K
FOSL icon
139
Fossil Group
FOSL
$349M
$970K 0.04%
+258,065
New +$728K
SRZN icon
140
Surrozen
SRZN
$255M
$949K 0.04%
+41,999
New +$679K
ASMB icon
141
Assembly Biosciences
ASMB
$526M
$948K 0.04%
+27,863
New +$897K
GOSS icon
142
CALL
Gossamer Bio
GOSS
$86.9M
$930K 0.04%
300,100
– –
NE icon
143
Noble Corp
NE
$6.37B
$918K 0.04%
32,500
-95,500
-75% -$2.82M
ADMA icon
144
PUT
ADMA Biologics
ADMA
$2.15B
$912K 0.04%
+50,000
New +$843K
INFU icon
145
InfuSystem Holdings
INFU
$242M
$901K 0.04%
+100,465
New +$961K
SPCE icon
146
Virgin Galactic
SPCE
$371M
$899K 0.04%
+280,160
New +$1.06M
VERI icon
147
Veritone
VERI
$112M
$891K 0.04%
+191,517
New +$1.03M
HCC icon
148
Warrior Met Coal
HCC
$4.45B
$882K 0.04%
10,000
-45,000
-82% -$3.38M
ARMP icon
149
Armata Pharmaceuticals
ARMP
$173M
$878K 0.04%
+139,860
New +$766K
FCEL icon
150
FuelCell Energy
FCEL
$1.69B
$877K 0.04%
+120,000
New +$981K
4 5
6
7 8

Similar funds

QOP
Quinn Opportunity Partners Charlottesville, Virginia $1.92B AUM 31.26% 1-Year Est. Return
RIL
Rothschild Investment LLC Chicago, Illinois $1.91B AUM 24.37% 1-Year Est. Return
MC
Maren Capital Chicago, Illinois $1.91B AUM 17.37% 1-Year Est. Return
RCAG
Rehmann Capital Advisory Group Lansing, Michigan $1.92B AUM 16.97% 1-Year Est. Return
BOH
Bank of Hawaii Honolulu, Hawaii $1.91B AUM 22.08% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
IAN
Integrated Advisors Network Dallas, Texas $1.91B AUM 24.91% 1-Year Est. Return

683 Capital Management's Q4 2025 Portfolio in Review

As of Q4 2025, 683 Capital Management held 255 positions worth $2.3B, up 20% from $1.91B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

683 Capital Management deployed $216M of net new capital in Q4 2025, opening 116 new positions and adding to 33 existing holdings. Its largest new stake was Kaspi.kz JSC: 265,000 shares worth $20.7M.

By sector, the portfolio is most concentrated in Healthcare at 22% of assets, down from 23% a quarter earlier, followed by Financials and Consumer Discretionary.

On the sell side, the largest reduction was Western Digital, an estimated $29.7M trimmed.

  • 683 Capital Management's largest Q4 2025 buy was Kaspi.kz JSC: 265,000 shares worth $20.7M.
  • 683 Capital Management added most to Mereo BioPharma in Q4 2025, an estimated $19.3M increase.
  • 683 Capital Management's biggest Q4 2025 reduction was Western Digital, cutting an estimated $29.7M.
  • 683 Capital Management fully exited Eli Lilly in Q4 2025, selling an estimated $21.8M.
  • 683 Capital Management's ten largest holdings make up 49% of its $2.3B portfolio in Q4 2025.
  • 683 Capital Management opened 116 new positions and closed 21 in Q4 2025.
  • 683 Capital Management's portfolio value rose 20% quarter-over-quarter to $2.3B.

Based on 683 Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.